Blood biomarkers indicative of Alzheimer’s disease (AD) pathology are altered in both
preclinical and symptomatic stages of the disease. Distinctive biomarkers may be optimal for the …

Importance Alzheimer disease (AD) pathology starts with a prolonged phase of β-amyloid (Aβ)
accumulation without symptoms. The duration of this phase differs greatly among …

Tau PET imaging has potential for elucidating changes in the deposition of neuropathological
tau aggregates that are occurring during the progression of Alzheimer disease (AD). This …

This study investigated differences in retrospective cognitive trajectories between amyloid
and tau PET biomarker stratified groups in initially cognitively unimpaired participants …

Background Characterizing cerebrovascular hemodynamics in older adults is important for
identifying disease and understanding normal neurovascular aging. Four-dimensional (4D) …

Introduction This study applies a novel algorithm to longitudinal amyloid positron emission
tomography (PET) imaging to identify age‐heterogeneous amyloid trajectory groups, estimate …

Clinical evidence shows vascular factors may co-occur and complicate the expression of
Alzheimer’s disease (AD); yet, the pathologic mechanisms and involvement of different …

Importance Characterization of early tau deposition in individuals with preclinical Alzheimer
disease (AD) is critical for prevention trials that aim to select individuals at risk for AD and …

Introduction Individuals with Down syndrome (DS) show enhanced amyloid beta (Aβ) deposition
in the brain. A new positron emission tomography (PET) index of amyloid load (Aβ L ) …

INTRODUCTION Our objective was determining the optimal combinations of cerebrospinal
fluid (CSF) biomarkers for predicting disease progression in Alzheimer's disease (AD) and …